Skip to content

Author

Umberto Quartetti

We have 1 of 12 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Reduction of interleukin-6 levels in patients with Friedreich's Ataxia treated with omaveloxolone.

Omav confirmed a favorable safety and tolerability profile in adult patients with FRDA in a real-world setting after 48 weeks of treatment, and a sustained reduction in IL-6 levels supports a potential direct immunomodulatory effect of the drug, consistent with its proposed disease-modifying activity.

V. Di Stefano, Salvatore Maria Lima, S. Campo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.